Synergy Pharmaceuticals, Inc Common Stock
SGYP
SGYP was delisted on the 7th of March, 2019.
143 hedge funds and large institutions have $436M invested in Synergy Pharmaceuticals, Inc Common Stock in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 60 increasing their positions, 32 reducing their positions, and 19 closing their positions.
88% more repeat investments, than reductions
Existing positions increased: 60 | Existing positions reduced: 32
5% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 19
2% less funds holding
Funds holding: 146 → 143 (-3)
39% less capital invested
Capital invested by funds: $717M → $436M (-$281M)
74% less call options, than puts
Call options by funds: $2M | Put options by funds: $7.67M
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$5.71M |
| 2 |
JP Morgan Chase
New York
|
+$4.83M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.72M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$4.56M |
| 5 |
Goldman Sachs
New York
|
+$3.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$25.7M |
| 2 |
TCP
Tourbillon Capital Partners
New York
|
-$18.5M |
| 3 |
Millennium Management
New York
|
-$13.6M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$13.5M |
| 5 |
TCM
TimesSquare Capital Management
New York
|
-$11.4M |
SGYP Hedge Fund Activity: Q3 2017 in Review
143 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals, Inc Common Stock (SGYP) for Q3 2017, worth a combined $436M — down 39% from $717M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of SGYP and 18 opened new positions — a net loss of 1 holder — while 32 trimmed existing stakes and 60 added.
The largest buyer was UBS Group, adding an estimated $5.71M. The largest seller was OrbiMed, cutting an estimated $25.7M.
- 143 institutional investors held Synergy Pharmaceuticals, Inc Common Stock (SGYP) as of Q3 2017, down from 146 in Q2 2017.
- Funds reported $436M of Synergy Pharmaceuticals, Inc Common Stock stock for Q3 2017, down 39% quarter-over-quarter.
- 18 funds opened new Synergy Pharmaceuticals, Inc Common Stock positions in Q3 2017 and 19 closed out, a net change of -1 holder.
- The largest Synergy Pharmaceuticals, Inc Common Stock buyer in Q3 2017 was UBS Group, an estimated $5.71M added.
- The largest Synergy Pharmaceuticals, Inc Common Stock seller in Q3 2017 was OrbiMed, an estimated $25.7M sold.
Based on aggregated 13F filings for Q3 2017.